April 22, 2018 11:19 PM ET


Company Overview of Celldex Therapeutics, Inc.

Company Overview

Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of various immunotherapy technologies and other cancer-targeting biologics. Its drug candidates include glembatumumab vedotin, an antibody-drug that is in Phase IIb study for the treatment of triple negative breast cancer and a Phase II study for the treatment of metastatic melanoma; Varlilumab, an immune modulating antibody that is in a Phase 1 study designed to enhance a patient's immune response against cancer; and CDX-3379, a human monoclonal antibody that is in Phase II study in combination with cetuximab for the treatment of head and neck squamous cell carcinoma. The company also d...

Perryville III Building

Suite 220

53 Frontage Road

Hampton, NJ 08827

United States

192 Employees





Key Executives for Celldex Therapeutics, Inc.

Founder, President, CEO & Director
Age: 55
Total Annual Compensation: $859.4K
Founder, Chief Scientific Officer and Executive Vice President
Age: 58
Total Annual Compensation: $548.8K
Chief Product Development Officer and Senior Vice President
Age: 45
Total Annual Compensation: $419.0K
Compensation as of Fiscal Year 2016.

Celldex Therapeutics, Inc. Key Developments

Celldex Therapeutics, Inc. Announces Promising Early Data from Investigator-Initiated Pilot Study Evaluating the Combination of CDX-301 and Stereotactic Body Radiotherapy

Celldex Therapeutics, Inc. announced promising early data from an investigator-initiated pilot study evaluating the combination of CDX-301 and stereotactic body radiotherapy (SBRT) in patients with advanced non-small cell lung cancer (NSCLC). CDX 301 (recombinant human Flt3 ligand) is a potent hematopoietic cytokine that uniquely expands dendritic cells and hematopoietic stem cells. This translational study is the culmination of significant preclinical research into strategically combining radiation and immunotherapy to effectively treat aggressive tumors and is supported by a Small Business Innovation Research (SBIR) grant from the National Cancer Institute to Celldex in collaboration with Albert Einstein College of Medicine, part of Montefiore. The concept that increasing the number of dendritic cells with Flt3 ligand combined with an ablative course of radiation to the primary tumor induces a systemic anti-tumor response, suppresses metastases and promotes survival and immune memory was demonstrated through preclinical studies led by Dr. Chandan Guha and colleagues at the Einstein College of Medicine. 1 Based on this seminal work, a Phase 2 pilot study of CDX-301 in combination with SBRT was initiated at the Montefiore Einstein Center for Cancer Care. The study is currently enrolling up to 29 patients, and the primary objective is progression-free survival at four months after treatment (PFS4). Key secondary objectives include evaluation of dose-limiting toxicities and response rate in non-irradiated tumors, where tumor shrinkage from radiation therapy or CDX-301 independently would not be expected. Responses were particularly impressive when classified by PERCIST (PET Response in Solid Tumors) criteria, in which a partial response is at least a 45% reduction of total glycolytic activity, a volumetric measure of disease burden. The presentation included data from nine patients, seven of whom were previously treated with anti-PD(L)1 checkpoint inhibitors. The one-week course of treatment included subcutaneous injections of CDX-301 and SBRT directed to a single lung tumor lesion.

Celldex Therapeutics, Inc. - Special Call

To discuss topline METRIC results

Celldex Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Year Ended December 31, 2017

Celldex Therapeutics, Inc. reported earnings results for the fourth quarter and year ended December 31, 2017. For the quarter, the company reported total revenue of $3.5 million in the fourth quarter of 2017 compared to $1.9 million a year ago. The increase in revenue was primarily due to the manufacturing service agreements with the International AIDS Vaccine Initiative and Frontier Biotechnologies, Inc. Net loss was $3.8 million or $0.03 per share for the fourth quarter of 2017 compared to a net loss of $32.3 million, or $0.30 per share for the comparable periods in 2016 For the year, the company reported total revenue of $12.7 million compared to $6.8 million for the comparable periods in 2016. Net loss was $93.0 million or $0.72 per share for the year ended December 31, 2017 compared to a $128.5 million, or $1.27 per share for the comparable periods in 2016.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
Tax Management Inc United States
John F. Kennedy Center For The Performing Arts United States
NYC2012, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Celldex Therapeutics, Inc., please visit www.celldex.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.